Navigation Links
Medisafe 1 Technologies One-Time Special Dividend Announced
Date:2/20/2013

JERUSALEM, February 20, 2013 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company intends to issue the one-time special dividend to all existing shareholders pursuant to the perpetual license sale of technology rights to SAFECODE DRUG TECHNOLOGIES CORP.

The dates of the dividend are as follows.

Ex-Dividend date for its dividend to its Shareholders on April 30 2013, record date on May 3 2013 and the payment date on May 6 2013.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
Jacob Elhadad , CEO
+972-524440000
Jacob.elhadad10@gmail.com

'/>"/>
SOURCE Medisafe 1 Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medisafe 1 Technologies Announces the Ex-Dividend Date on April 30 2013, Record Date on May 3 2013 and the Payment Date on May 6 2013
2. Medisafe 1 Technologies Signs the $7MM Perpetual License Agreement
3. Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
4. Medisafe 1 Technologies Anticipates a Special Dividend of $0.01 (One Cent) to Each Shareholder of One Common Stock pending the $7MM Perpetual License Sale of Technology Rights
5. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
6. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
7. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
8. Leading Breast Surgeons Highlight Techniques and Visualization Technologies for Improved Clinical and Aesthetic Outcomes at Invuitys Surgeon Educational Symposium
9. TOA Technologies mobile healthcare service solutions unite personalized service and efficiency to deliver an enhanced patient experience
10. Frost & Sullivan: Clinical Trial-based Evidence Vital to Obtain Venture Capital Funding for Wireless Patient Monitoring Technologies
11. Zebra Technologies Connects the Dots Between the Patient Experience and Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4
(Date:2/28/2015)... 2015 For those people who are ... Mesothelioma Applied Research Foundation (Meso Foundation) will ... 3, starting at 9:30 AM. , The live broadcast ... broadcast can be accessed through any browser on a ... The Symposium is a unique event that covers important ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... 2015 Memphis, TN: MedixSafe has retracted ... a new security reader named Guardian 2. The ... a new biometric scanner that significantly increases the ... the new biometric scanner provides fast and easy ... MedixSafe narcotics lockers with Vanguard technology ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... CARLOS, Calif., Nov. 7 Nektar,Therapeutics (Nasdaq: NKTR ... quarter that ended September 30, 2007. Revenue totaled ... to,$58.6 million in the third quarter of 2006. For ... revenue of $207.3 million,compared to $147.8 million in the ...
... Nov. 7 Rapid Pathogen Screening Inc.,(RPS) -- ... ocular,diseases -- announced today that the American Medical ... code that will cover the,RPS Adeno Detector(TM), effective ... code,for "Infectious agent antigen detection by immunoassay with ...
... 7 Mesa Laboratories,Inc. (Nasdaq: MLAB ) today reported ... and six months ended September 30, 2007. Highlights: ... * Second quarter net income increases 40% ... the second quarter of fiscal 2008, net sales increased 16 ...
... Corrective cardiac surgery is not to blame, study suggests , , ... in babies born with certain heart defects, new research shows. ... delay found in premature infants, the researchers added. , Babies ... developmental delays, but whether the delays were due to the ...
... This past weekend study,results on "Molecular Breast ... at the Nuclear Science Symposium and Medical,Imaging Conference ... laboratory study was to evaluate the performance of ... in which,the two imaging detectors are positioned on ...
... 7 Today, the release of,Emerging Answers 2007: ... Sexually Transmitted Disease, a report authored by Douglas,Kirby, ... once,again, that the $1.5 billion federal and state ... money., The report, commissioned by the National ...
Cached Medicine News:Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 2Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 3Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 4Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 5Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 6Health News:Nektar Therapeutics Announces Third Quarter 2007 Financial Results 7Health News:American Medical Association Clears Path for Adenoviral Conjunctivitis - 'Pink Eye' - Detector 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 3Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 4Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 5Health News:Heart Defects Can Delay Baby's Brain Development 2Health News:Heart Defects Can Delay Baby's Brain Development 3Health News:Heart Defects Can Delay Baby's Brain Development 4Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 2Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 3Health News:New Study - Same Verdict 2
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... derives its name from its first known ... The majority of PSA circulates bound to ... concentrations of PSA are elevated in patients ... and prostatitis [1-3]. In addition, PSA serum ...
... of Vision and Contrast Sensitivity. The ... and glare luminance levels for accurate ... with/without glare and background luminance Comply ... standards. All Light Levels Microprocessor Controlled ...
Contrast Sensitivity is Recognized as a Valuable Tool for Measuring Functional Vision Loss Caused by Early Eye Disease. Distance Test S.W.C.T. 201: Size 27in x 37 in (68.58cm x 93.98cm),Can be Wal...
Medicine Products: